Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial

Hereditary hemorrhagic telangiectasia is a rare but ubiquitous genetic disease. Epistaxis is the most frequent and life-threatening manifestation and tacrolimus, an immunosuppressive agent, appears to be an interesting new treatment option because of its anti-angiogenic properties. Our objective was...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Med
Auteurs principaux: Dupuis-Girod, Sophie, Fargeton, Anne-Emmanuelle, Grobost, Vincent, Rivière, Sophie, Beaudoin, Marjolaine, Decullier, Evelyne, Bernard, Lorraine, Bréant, Valentine, Colombet, Bettina, Philouze, Pierre, Bailly, Sabine, Faure, Frédéric, Hermann, Ruben
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7287684/
https://ncbi.nlm.nih.gov/pubmed/32357559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9051262
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires